Pharmacyclics, Inc. Prices Public Offering of Common Stock

          Pharmacyclics, Inc. Prices Public Offering of Common Stock

PR Newswire

SUNNYVALE, Calif., March 8, 2013

SUNNYVALE, Calif., March 8, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ:
PCYC), a clinical stage biopharmaceutical company focused on developing and
commercializing innovative small-molecule drugs for the treatment of cancer
and immune mediated diseases, today announced the pricing of a previously
announced underwritten registered public offering of 2,200,000 shares of its
common stock, representing approximately 3.1% of the shares of common stock
currently outstanding, at a public offering price of $94.20 per share. All of
the shares are being sold by Pharmacyclics. The offering is expected to close
on March 13, 2013, subject to customary closing conditions.

J.P. Morgan Securities LLC is acting as sole manager for the offering.
Pharmacyclics has granted the underwriter a 30-day option to purchase up to an
additional 330,000 shares of common stock to cover over-allotments, if any.

Pharmacyclics intends to use the net proceeds from this offering to accelerate
commercial readiness for Ibrutinib post Breakthrough Therapy Designation, to
advance its clinical pipeline, including expanding clinical development of
Ibrutinib in additional indications, to evaluate strategic opportunities to
potentially add synergistic assets, and for general corporate purposes.

The shares will be issued pursuant to an automatic shelf registration
statement on Form S-3 previously filed with the Securities and Exchange
Commission, Registration No. 333-187104. A preliminary prospectus supplement
related to the offering has been filed with the Securities and Exchange
Commission. A final prospectus supplement related to the offering will be
filed with the Securities and Exchange Commission.

This announcement shall not constitute an offer to sell or the solicitation of
an offer to buy any securities of Pharmacyclics, nor shall there be any offer
or sale of securities in any state or jurisdiction in which an offer,
solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of any such state or jurisdiction. Copies of the
final prospectus supplement, when available, and accompanying prospectus may
be obtained from J.P. Morgan Securities LLC via Broadridge Financial
Solutions, 1155 Long Island Avenue, Edgewood, New York, 11717 or by calling
toll-free (866) 803-9204.

About Pharmacyclics

Pharmacyclics, Inc., headquartered in Sunnyvale, California, is a
clinical-stage biopharmaceutical company focused on developing and
commercializing innovative small-molecule drugs for the treatment of cancer
and immune mediated diseases. Its corporate mission and goal is to build a
viable biopharmaceutical company that designs, develops and commercializes
novel therapies intended to improve quality of life, increase duration of life
and resolve serious medical healthcare needs; and to identify promising
product candidates based on scientific and administrational development
expertise, develop our product candidates in a rapid, cost-efficient manner
and pursue commercialization and/or development partners when and where
appropriate.

Presently, Pharmacyclics has three product candidates in clinical development
and several research molecules in lead optimization. The Company is committed
to high standards of ethics, scientific rigor, and operational efficiency as
it moves each of these programs toward viable commercialization.

SOURCE Pharmacyclics, Inc.

Website: http://www.pharmacyclics.com
Contact: Pharmacyclics, Inc. Contacts, Joshua T. Brumm, Executive Vice
President, Finance, +1-408-215-3311, or Ramses Erdtmann, Vice President of
Investor Relations, +1-408-215-3325